Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646215 | 0.90 | ECE1 (0.41) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL5763557 | 0.90 | ECE1 (0.41) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL13340947 | 0.87 | POLB (0.49) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL15341340 | 0.87 | PDK1 (0.45) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL1058639 | 0.87 | POLB (0.49) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL8699830 | 0.87 | POLB (0.49) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL1058641 | 0.87 | POLB (0.49) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL9386719 | 0.83 | PDK1 (0.40) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL13297956 | 0.83 | ABCB1 (0.41) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL6643705 | 0.82 | POLB (0.44) | PDK1PDK2PDK3PDK4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1377577-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | Sankyo Company Limited (JP) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | IL1B, IL1A, STAT6 | PDK1 348/4885PDK2 152/4885PDK3 90/4885 |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | PDK1 1988/4885PDK2 677/4885PDK3 1410/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | PDK1 1902/4885PDK2 657/4885PDK3 1398/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | PDK1 2676/4885PDK2 1109/4885PDK3 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.